Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1

American Journal of Medical Genetics

Volumn 127, Issue 3, 2004, Pages 224-229

  Blazo, M A ^a   Lewis, R A ^a   Chintagumpala, M M ^a,b   Frazier, M ^a   MeCluggage, C ^c   Plon, Sharon E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Neurofibromatosis; Neuroimaging; Optic pathway tumor

Indexed keywords

CARBOPLATIN; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; EARLY DIAGNOSIS; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; OPTIC NERVE ATROPHY; OPTIC PATHWAY TUMOR; OPTIC TRACT; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; STRABISMUS; SYMPTOM; TUMOR; TUMOR GROWTH; UNITED STATES; VISUAL IMPAIRMENT;

EID: 2542445609     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.20650     Document Type: Article

References (21)

1. Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH. 2001. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 33(4):314-323.
2. Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG. 2001. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: Relation to tumor location by magnetic resonance imaging. Am J Ophthalmol 131(4):442-445.
3. DeBella K, Szudek J, Friedman JM. 2000. Use of the National Institutes of Health Criteria for diagnosis of Neurofibromatosis 1 in children. Pediatrics 105:608.
4. Deliganis AV, Geyer JR, Berger MS. 1996. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 38(6):1114-1119.
5. Health Supervision for Children With Neurofibromatosis. 1995. American Academy of Pediatrics Committee on Genetics. Pediatrics 96:368.
6. Inskip PD, Linet MS, Heineman EF. 1995. Etiology of brain tumors in adults. Epidemiol Rev 17:382-414.
7. Kluwe L, Hagel C, Tatagiba M, Thomas S, Stavrou D, Ostertag H, von Deimling A, Mautner VF. 2001. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J Neuropathol Exp Neurol 60(9):917-920.
8. Ledbetter DH, Rich DC, O'Connell P, Leppert M, Carey JC. 1989. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet 44:20.
9. Lee AG. 1999. A practice pathway for the management of gliomas of the anterior visual pathway: An evidence based approach. Neuro-Ophthalmology 22(3):139-155.
10. Lewis RA, Gerson PL, Axelson KA, Riccardi VM, Whitford RP. 1984. Von Recklinghausen neurofibromatosis: Incidence of optic gliomata. Ophthalmology 91:929-935.
11. Listernick R, Charrow J, Greenwald MJ, Esterly NB. 1989. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 114:788-792.
12. Listernick R, Charrow J, Greenwald MJ. 1992. Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results. J Pediatr 121(4):584-587.
13. Listernick R, Charrow J, Greenwald MJ, Mets M. 1994. Natural history of optic pathway tumors in children with neurofibromatosis: A longitudinal study. J Pediatr 125(1):63-66.
14. Listernick R, Darling C, Greenwald M, Strauss L, Charrow J. 1995. Optic pathway tumors in children: The effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127(5):718-722.
15. Listernick R, Louis DN, Packer RJ, Gutmann DH. 1997. Optic pathway gliomas in children with neurofibromatosis type 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 41:143-149.
16. Listernick R, Charrow J, Gutmann DH. 1999. Intracranial Gliomas in Neurofibromatosis Type I. Am J Med Genet 89(1):38-44.
17. Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, James HE, Duffner PK, Kun LE. 2000. Carboplatin is effective therapy for young children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro-Oncology 2(4):213-220.
18. Massry GG, Morgan CF, Chung SM. 1997. Evidence of optic pathway gliomas after previously negative neuroimaging. Ophthalmology 104(6):930-935.
19. Neurofibromatosis Conference Statement. 1988. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575.
20. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN. 1993. Carboplatin and vincristine for progressive low-grade gliomas of childhood. J Clin Oncol 11:850-856.
21. Riccardi VM. 1992. Neurofibromatosis: Phenotype, natural history, and pathogenesis. Baltimore: Johns Hopkins University Press.